MARKETSQUIET
1 hour ago
Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript
SIGNALSMONITORMARKETS
What's happening
SignalsMonitor is following this as a markets story. Seeking Alpha is the outlet attached so far. The first report grouped here was at 27 Oct 2026, 16:39 UTC. The headline in use is “Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by Seeking Alpha
Reported by 1 outlet
- Seeking Alpha